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significantly different levels in the hydrophilic phase of OB vs NW. 29 
Discussion: Placental metabolome analysis of obese pregnancies showed 30 
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production, supporting a shift towards higher placental metabolism. OB 33 
placentas also showed a specific fatty acids profile suggesting a 34 
disruption of LC-PUFA biomagnification. This study can lay the 35 
foundation to further metabolomic placental characterization in 36 
maternal obesity. Metabolic signatures in obese placentas may reflect 37 
changes occurring in the intrauterine metabolic environment, which may 38 
affect the development of adult diseases. 39 
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ABSTRACT 1 
Introduction: Metabolomics identifies phenotypical groups with specific metabolic profiles, 2 
being increasingly applied to several pregnancy conditions. This is the first preliminary study 3 
analyzing placental metabolomics in normal weight (NW) and obese (OB) pregnancies. 4 
Methods: Twenty NW (18.5 ≤BMI< 25 kg/m2) and eighteen OB (BMI≥ 30 kg/m2) 5 
pregnancies were studied. Placental biopsies were collected at elective caesarean section. 6 
Metabolites extraction method was optimized for hydrophilic and lipophilic phases, then 7 
analyzed with GC-MS. Univariate and PLS-DA multivariate analysis were applied. 8 
Results: Univariate analysis showed increased uracil levels while multivariate PLS-DA 9 
analysis revealed lower levels of LC-PUFA derivatives in the lipophilic phase and several 10 
metabolites with significantly different levels in the hydrophilic phase of OB vs NW. 11 
Discussion: Placental metabolome analysis of obese pregnancies showed differences in 12 
metabolites involved in antioxidant defenses, nucleotide production, as well as lipid synthesis 13 
and energy production, supporting a shift towards higher placental metabolism. OB placentas 14 
also showed a specific fatty acids profile suggesting a disruption of LC-PUFA 15 
biomagnification. This study can lay the foundation to further metabolomic placental 16 
characterization in maternal obesity. Metabolic signatures in obese placentas may reflect 17 
changes occurring in the intrauterine metabolic environment, which may affect the 18 
development of adult diseases. 19 
 20 
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 23 
ABBREVIATIONS 24 
AMDIS: Automated Mass spectral 25 
Deconvolution and Identification System 26 
ANOVA: ANalysis Of VAriance 27 
BF3: boron trifluoride 28 
BMI: Body Mass Index 29 
CV: Cross Validation 30 
DHA: DocosaHexaenoic Acid 31 
DNA: DeoxyriboNucleic Acid 32 
FDR: False Discovery Rate 33 
FIGO: International Federation of Obstetrics 34 
and Gynecology 35 
GC-MS: Gas Chromatography-Mass 36 
Spectrometry 37 
GDM: Gestational Diabetes Mellitus 38 
GMD: Golm Metabolome Database 39 
4 
 
GWG: Gestational Weight Gain 1 
HSD: Honest Significant Difference 2 
IGF-1: Insuline-like Growth Factor-1 3 
LC-MS: Liquid Chromatograph Mass 4 
SpectrometersLC-PUFA: Long Chain- 5 
Polyunsaturated Fatty Acids 6 
MS: Mass Spectrometry 7 
MSTFA: N-Methyl-Ntrimethylsilyltrifluoroacetamide 8 
mTOR: mammalian Target Of Rapamycin 9 
NAD: Nicotinamide Adenine Dinucleotide 10 
NADPH: Nicotinamide Adenine 11 
Dinucleotide Phosphate 12 
NIST08: National Institute of Standards and 13 
Technology mass spectral database 14 
NMR: Nuclear Magnetic Resonance 15 
OGTT: Oral Glucose Tolerance Test 16 
PBS: Phosphate Buffered Saline 17 
PLS-DA: Partial Least Square-Discriminant 18 
Analysis 19 
RT: Room Temperature 20 
 21 
HIGHLIGHTS 22 
Maternal pregestational BMI determines different placental metabolite concentration 23 
Obese placentas lipophilic profile supports LC-PUFA biomagnification disruption 24 
The hydrophilic profile suggests a shift towards higher obese placental metabolism 25 
  26 
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MAIN TEXT 1 
INTRODUCTION 2 
Obesity is spreading worldwide with almost epidemic proportions, representing a risk factor 3 
for adverse pregnancy outcomes and offspring’s complications [1-2]. Maternal obesity is 4 
characterized by calorie imbalance and incorrect dietary intake and has been associated with a 5 
lipotoxic placental environment, defined by decreased regulators of angiogenesis and increased 6 
markers of inflammation and oxidative stress [3]. This adverse intrauterine environment may 7 
directly affect placental function and metabolism [4,5]. Similarly to what occurs with maternal 8 
diabetes, increased maternal Body Mass Index (BMI), together with fetal sex, is associated with 9 
decreased placental efficiency and histopathologic findings typical of hypoxia and 10 
inflammation [3-6]. 11 
Metabolomics applies a holistic approach to study the whole metabolite content of cells, tissues 12 
or bio-fluids. Metabolomic analysis has recently found applications in several pregnancy-13 
related conditions [7-13] allowing for the recognition of different phenotypical groups due to 14 
their characteristic metabolic profile. Most of these works reported metabolomic analysis of 15 
bio-fluids such as blood, urine or amniotic fluid [7-13]. 16 
To the best of our knowledge, there are only few metabolomic studies on placenta tissue extracts 17 
using Mass Spectrometry (MS) [14-20] or Nuclear Magnetic Resonance (NMR) spectroscopy 18 
[21-23]. Placental metabolome changes in relation to maternal obesity were only investigated 19 
in rats following different diets [20]. 20 
The aim of this preliminary study is to examine key placental metabolites associated with 21 
maternal obesity. Obese patients were also evaluated according to gestational diabetes. 22 
Hydrophilic and lipophilic metabolites were studied through GC-MS (Gas Chromatography-23 
Mass Spectrometry) platform, followed by multivariate statistic protocols. 24 
 25 
 26 
METHODS 27 
1.Population 28 
The protocol of the study was approved by the Ethical Committee of the Sacco Hospital (Milan) 29 
and all women signed a written informed consent. Only singleton spontaneous pregnancies, 30 
with maternal age between 18 and 40 years and of Caucasian ethnicity were included in the 31 
study. Exclusion criteria were maternal preexisting diseases, fetal and maternal infections, 32 
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alcohol or drugs abuse, fetal malformations or chromosomal disorders, BMI< 18.5 or BMI 1 
between 25-30. Pregnant women were allocated into two different groups based on their pre-2 
gestational BMI according to the Institute of Medicine (IOM) guidelines [24]: 3 
 Normal weight (NW) (18.5 ≤BMI< 25 Kg/m2), n= 20 4 
 Obese (OB) (BMI≥ 30 Kg/m2), n= 18 5 
Obese patients were given specific nutritional advice and recommendations on weight gain in 6 
pregnancy. Eight obese women had a diagnosis of Gestational Diabetes Mellitus (GDM) 7 
[OB/GDM(+)] based on an Oral Glucose Tolerance Test (OGTT, 75 g), according to FIGO 8 
guidelines [25]. OB/GDM(+) were constantly checked for glycaemia and were given lifestyle 9 
and dietary indications for glycemic control. None of the studied women needed insulin 10 
therapy. 11 
Maternal medical history, demographic, anthropometric, and obstetric data, as well as neonatal 12 
outcome data were recorded at recruitment and after delivery. Maternal gestational weight gain 13 
(GWG) was recorded. 14 
 15 
2.Sample Collection 16 
Placentas from elective caesarean section were measured recording placental weight, area and 17 
thickness as previously described [5]. Placental tissue was collected from a not-impaired part 18 
of the placental disc, after discarding the maternal decidua layer, washed in PBS, then cut into 19 
small pieces and immediately frozen in liquid nitrogen. The tissue was then transferred into 20 
a -80°C freezer. Samples were sent to the University of Cagliari to be analyzed by the GC-MS 21 
platform. 22 
 23 
3.Sample Preparation 24 
The extraction method was optimized from literature methods [17-18, 26-27]. A piece of 25 
placental tissue of about 100 mg was rapidly weighed, put in a glass mortar on ice with 1.9 mL 26 
of chloroform/methanol/water (1.4/1.4/1, 700/700/500 l) and homogenized with a Potter-27 
Elvehjem homogenizer for 2 minutes. The mixture was kept at 4°C for 15 min, then centrifuged 28 
at 14000 rpm for 10 min at 4°C. The upper (hydrophilic) and lower (lipophilic) phases were 29 
separated: the hydrophilic was dried in a vacuum concentrator (Eppendorf Concentrator Plus) 30 
overnight; the lipophilic in a glass vacuum desiccator under fume-hood for 2 h. The volume of 31 
extraction solution was normalized to 100 mg of tissue, with 1000 L of the upper phase and 32 
7 
 
600 L of the lower being dried down for 100 mg of tissue [17]. The dried fractions were stored 1 
at -80°C until analysis. 2 
 3 
Hydrophilic Phase 4 
30 µL of a solution of methoxylamine hydrochloride in pyridine (0.24 M) were added to each 5 
sample, then vortex mixed and left for 17 h at room temperature (RT). 30 µL of MSTFA were 6 
added and left for 1 h at RT. Just before GC-MS analysis, samples were diluted with a hexane 7 
solution (600 µL) of tetracosane (0.006 mg/mL) as internal standard, then analyzed using a 8 
Agilent 5977B interfaced to the GC 7890B with a DB-5ms column (J & W) [injector 9 
temperature at 230°C, detector temperature at 280°C, helium carrier gas flow rate of 1 mL/min]. 10 
The GC oven temperature program was 90°C for 1 min, ramped by 10°C/min to 270°C with 7 11 
min hold time. The sample (1 µL) was injected in split (1:10) mode. After a solvent delay of 3 12 
min, mass spectra were acquired in full scan mode using 2.28 scans/s with a mass range of 50–13 
700 Amu. 14 
 15 
Lipophilic Phase 16 
150 µL of chloroform:methanol (1:1) and 100 µL of 14% BF3 in methanol were added to each 17 
vial, samples were vortex mixed and left for 90 min at 80ºC into an heating block. Once cooled, 18 
600 µL hexane and 300 µL water were added, samples were vortex mixed and centrifuged for 19 
2 min at 1400 rpm. The organic layer (upper) was transferred into glass vials and dried in a 20 
vacuum concentrator. Samples were then reconstituted with 400 µL hexane and injected to be 21 
analyzed with Agilent 5977B interfaced to the GC 7890B equipped with a DB-5ms column (J 22 
& W) [injector temperature at 230°C, detector temperature at 280°C, helium carrier gas flow 23 
rate of 1 mL/min]. The initial column temperature was 60ºC for 2 minutes, ramped by 15ºC/min 24 
to 150ºC, and then by 4°C/min to 230ºC, hold for 20 min. The sample (1 µL) was injected in 25 
split (1:10) mode. After a solvent delay of 4 min, mass spectra were acquired in full scan mode 26 
using 2.28 scans/s with a mass range of 50–700 Amu. 27 
 28 
4.Data Analysis 29 
Each acquired chromatogram was analyzed with the free software AMDIS 30 
[http://chemdata.nist.gov/mass-spc/amdis] using an in-house made library comprising 222 31 
metabolites. Some metabolites were identified using NIST08 and the GMD [http://gmd.mpimp-32 
golm.mpg.de/] the metabolite was considered positively identified with a match factor 70%. 33 
For lower values the metabolite was labelled as ‘unknown’. The AMDIS analysis of the 34 
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hydrophilic phase analysis produced a matrix containing 78 metabolites: 55 accurately 1 
identified, 1 unknown compound matching an equally unknown of GMD group, and 22 2 
unknown molecules recurring in every sample. The lipophilic phase produced a matrix 3 
containing 22 metabolites: 17 accurately identified compounds and 5 unknown molecules 4 
recurring in every sample. The obtained data matrices were successively subjected to statistical 5 
analysis. 6 
 7 
5.Statistical Analysis 8 
Sample size was adequate to assure the minimum precision requested for a pilot study [28]. 9 
Clinical characteristics and data displayed a normal distribution (Kolmogorov-Smirnov Test), 10 
and were thus compared between groups with parametric statistics (t-test). Correction to t-test 11 
was applied when the equality of variances assumption was violated (Levene’s test). 12 
Differences were considered statistically significant when p ≤ 0.05. 13 
Univariate analysis (ANOVA, ANalysis Of VAriance, and t-test) and multivariate models 14 
based on Partial Least Square-Discriminant Analysis (PLS-DA) were performed in 15 
MetaboAnalyst 3.0 [http://www.metaboanalyst.ca/] that allows to perform both analyses 16 
in the same session [29-31]. Raw data matrix was submitted to missing value estimation 17 
replacing all the missing values with the half of the minimum positive values in the original 18 
data, normalization by sum, Log transformation, and auto scaling and then used for both 19 
univariate and multivariate analyses. PLS-DA models were submitted to Cross Validation (CV) 20 
for the evaluation of statistical parameters (correlation coefficient- R2, CV coefficient Q2). This 21 
allowed to determine the optimal number of components for the model description. The 22 
permutation test was then applied to each model to investigate its predictive ability using the 23 
prediction accuracy test to set a permutation number (n=100 and p < 0.01). 24 
 25 
RESULTS 26 
Characteristics of the Population 27 
Maternal and delivery characteristics of the two study groups are reported in Table 1. No 28 
significant differences were observed in fetal and placental data at delivery between OB and 29 
NW. Moreover we found no significant differences between OB/GDM(+) and OB/GDM(-) 30 
except for maternal basal glycaemia (81.9 ± 7.0 vs 98.0 ± 7.9 mg/dL respectively, p ≤ 0.01) and 31 
placental weight (466.4 ± 65.7 vs 561.1 ± 67.5 g respectively, p ≤ 0.01) [data not shown]. 32 
 33 
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Hydrophilic Phase 1 
 2 
ANALYSIS IN OBESE vs NORMAL WEIGHT 3 
Univariate analysis (t-test) revealed a significantly increased concentration of the metabolite 4 
uracil (p-value = 0.0005, False Discovery Rate FDR= 0.034). Multivariate PLS-DA analysis 5 
was then performed: this model showed good statistical significance (accuracy= 0.77 R2 = 0.79 6 
Q2 = 0.48. CV method: 10-fold CV, performance measure p < 0.01) [Figure 1A]. In obese 7 
placentas higher levels of nucleobases (uracil, hypoxanthine and a not clearly identified purine 8 
derivative), glucose-6-phosphate, 3-phoshoglycerate, glycerol, nicotinamide and the amino 9 
acids tyrosine, isoleucine, phenylalanine, leucine and serine were found. On the other side lower 10 
amounts of the amino acids lysine, taurine, aspartic acid and glutamine, along with the 11 
nucleosides inosine and guanosine, an inositol isomer and gluconic acid were detected [Figure 12 
1B]. 13 
 14 
DIFFERENCES IN RELATION TO GDM 15 
We then explored the possible role of GDM in the hydrophilic metabolites profile of obese 16 
pregnant women. Univariate data analysis (ANOVA with Tukey’s HSD, Honest Significant 17 
Difference, post-hoc test) of the three classes OB/GDM(+), OB/GDM(-) and NW, gave no 18 
significant results. Multivariate data analysis (PLS-DA model) of the three classes 19 
OB/GDM(+), OB/GDM(-) and NW, gave accuracy= 0.61 R2 = 0.83 Q2 = 0.55. CV method: 10-20 
fold CV, performance measure p < 0.01 [Figure S1A and S1B]. 21 
 22 
Lipophilic Phase 23 
 24 
ANALYSIS IN OBESE vs NORMAL WEIGHT 25 
Univariate analysis (t-test) revealed no significant differences in metabolite concentration. 26 
Multivariate PLS-DA analysis was then performed [Figure 2A]. This model showed good 27 
statistical significance: accuracy= 0.86 R2 = 0.62 Q2 = 0.33; [CV] method: 10-fold CV, 28 
performance measure p < 0.01. The most interesting metabolites were represented by palmitic 29 
acid, showing higher levels in obese subjects, and DHA (DocosaHexaenoic Acid), arachidonic 30 
and stearic acid, presenting lower levels [Figure 2B]. 31 
 32 
DIFFERENCES IN RELATION TO GDM 33 
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We then explored the possible role of GDM in the lipophilic metabolites profile of obese 1 
pregnant women. 2 
Univariate data analysis (ANOVA with Tukey’s HSD post-hoc test) of the three classes 3 
OB/GDM(+), OB/GDM(-) and NW, gave no significant result. 4 
Similarly, multivariate data analysis (PLS-DA model) of the three classes OB/GDM(+), 5 
OB/GDM(-) and NW, gave no significant result (p = 0.20). 6 
 7 
DISCUSSION 8 
To our knowledge, this is the first study providing preliminary data on a broad range of 9 
metabolites in obese placentas delivered by elective caesarean section, thus avoiding molecular 10 
alterations due to labor. We applied metabolomics to investigate possible placental metabolic 11 
differences that can be relevant in two extreme maternal groups of the BMI scale: obese and 12 
normal weight. Of note, this study involved pregnant women with a well characterized clinical 13 
condition, undergoing regular prenatal checks in a dedicated clinic, and provided with 14 
nutritional and life style advice. This resulted in non-complicated maternal and fetal outcomes, 15 
and normal birthweights. Nonetheless, important differences were observed in the placental 16 
metabolites. These results may carefully be considered as potential markers for development of 17 
adult diseases. 18 
 19 
Hydrophilic Phase 20 
GC-MS analysis of the hydrophilic phase revealed altered amounts of several metabolites in 21 
obese placentas. 22 
In our study we found significant changes in several amino acids, with OB showing increased 23 
levels of tyrosine, isoleucine, phenylalanine, leucine and serine and lower amounts of lysine, 24 
taurine, aspartic acid and glutamine. Amino acids are accumulated within the placenta by active 25 
transport systems located on the microvillus membrane [36, 37]. Taurine is an aminosulfonic 26 
metabolite with lower levels in obese or diabetic subjects [38]. Indeed, decreased taurine 27 
transporter activity has been previously reported in placental villous explants of obese 28 
pregnancies [39]. With the exception of taurine, maternal obesity has been associated with 29 
enhanced placental transporters, mTOR, and IGF-1 signaling pathways activity [40]. We have 30 
also previously reported higher umbilical amino acid concentrations in pregnancies with 31 
gestational diabetes [41]. However, in this study obese subjects showed higher values of 32 
tyrosine, isoleucine, phenylalanine, leucine and serine but decreased levels of lysine, aspartic 33 
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acid and glutamine. Disrupted placental metabolism may account for most of the above 1 
mentioned amino acids alterations in obese women. Specifically, we recently observed 2 
increased mitochondrial DNA content in placentas of obese women [42] potentially leading to 3 
decreased fetal oxygen availability and thus altered metabolism [43-44]. Moreover, changes in 4 
metabolic pathways between the placenta and the fetal liver for glutamine and glutamate have 5 
been proposed [37], possibly due to fetal liver overgrowth [40]. Furthermore, similar alterations 6 
in amino acid levels were previously reported for hyperglycemic mothers [45]. 7 
Many of the amino acid that we found altered in obese placentas, together with other impaired 8 
metabolites (such as glycerol, uracile, hypoxanthine, a purine derivative, nicotinamide, glucose-9 
6-P, 3-phosphoglycerate, guanosine and inosine) are involved in metabolic pathways 10 
supporting nucleotide production, antioxidant defenses and lipid synthesis. Serine has a 11 
complex metabolism, being involved in several pathways. Among them, serine involvement in 12 
the folate cycle, can contribute to mitochondrial NADPH production [46]. Nicotinamide, an 13 
important component of NAD+-NADH co-enzymatic factor, is involved in mitochondrial 14 
energy production and in several redox transformations [47]. Interestingly, impaired global 15 
gene profiling related to mitochondrial dysfunction and altered energy production was reported 16 
in obese placentas and maternal blood [48-49]. Glycerol is a key intermediate in lipid and 17 
energy metabolism through triglycerides, relevant for energy storage. Its increase may be 18 
related to enhanced placental fatty acid availability and uptake from the maternal circulation of 19 
obese women [32]. 20 
Finally, inositol and gluconic acid lower amounts suggest a potentially reduced carbohydrate 21 
metabolism leading to enhanced insulin sensitivity [50]. 22 
 23 
Lipophilic Phase 24 
PLS-DA analysis showed interesting differences in placentas from obese women compared to 25 
controls. Interestingly, significantly lower levels of LC-PUFA (Long Chain-Polyunsaturated 26 
Fatty Acids) derivatives, arachidonic acid and DHA, were observed. The saturated palmitic acid 27 
was instead significantly increased. Changes in the maternal lipid profile have been reported in 28 
obesity, with increased triglycerides and decreased levels of high density lipoproteins [32]. 29 
Moreover, placental expression of fatty acid binding proteins is stimulated in obesity [33] 30 
together with higher lipid accumulation. Our results confirm and expand these observations 31 
indicating that obese women, independently of diabetes, show disruption of the physiologic 32 
LC-PUFA biomagnification, leading to decreased availability of arachidonic acid and DHA for 33 
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the fetus. This can increase the risk of adverse fetal outcomes and of developing a number of 1 
chronic diseases (e.g. metabolic and cardiovascular diseases) throughout postnatal life [34-35]. 2 
 3 
Limitations 4 
This study shows preliminary data in a limited population sample size. 5 
As such, the aim of this work was to identify metabolic perturbations in our samples of OB and 6 
NW placentas. Thus, here we report preliminary results and no definitive conclusion can be 7 
drawn from our data. However, this study provides interesting driving information for future 8 
metabolic pathways analysis, with a larger sample size. 9 
Obese pregnant women were carefully selected and matched to control pregnancies with similar 10 
characteristics except for BMI. For this reason, these results cannot be extended to the general 11 
obese population, since their favorable pregnancy outcomes were likely modulated by optimal 12 
prenatal care in these women. 13 
This study applied the same analytical platform (GC-MS) to both hydrophilic and lipophilic 14 
phase. LC-MS instruments are the most used for lipid profiling studies, allowing for the 15 
detection of a very large number of metabolites, covering all lipid classes. Nevertheless, the 16 
easier identification of metabolites provided by GC-MS, allowed to get interesting information, 17 
although not exhaustive, for this preliminary study. 18 
Another potential limitation is that, due to the small amount of tissue available, no pool sample 19 
was prepared. 20 
 21 
Conclusions 22 
Placental metabolome analysis of obese pregnancies suggested changes in metabolites’ 23 
concentrations associated with obesity, specifically higher glycerol levels, with a similar trend 24 
for a number of fatty acids. Differences were also found for some amino acids and metabolites 25 
involved in nucleotide production, antioxidant defenses and lipid synthesis, suggesting a 26 
generalized shift towards higher placental metabolism. 27 
This study can lay the foundation to further metabolomic placental characterization in the 28 
context of obesity. This can represent an additional missing link combining the two separated 29 
biological compartments of maternal blood and amniotic fluid, already investigated in other 30 
studies [6,7,9,11]. 31 
Moreover, future works based on these preliminary data will help identifying a specific 32 
placental phenotype of obese pregnancies, even in the setting of optimal prenatal care and 33 
13 
 
pregnancy outcomes. These data are not unexpected and lead to two major conclusions: 1) the 1 
need to optimize maternal BMI before conception and 2) the presence of specific metabolic 2 
signatures that may reflect underlying changes in the intrauterine metabolic environment. 3 
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TABLE 1 1 
 
 
 
NW 
n=20 
 
OB 
n=18 
 Maternal Age [yrs] 33.7 ± 5.7 33.9 ± 5.2 
Maternal Maternal Pre-Pregnancy BMI [kg/m2] 21.5 ± 1.6 36.4 ± 4.8 *** 
Data Maternal GWG [kg] 11.2 ± 3.6 8.8 ± 4.0 
 Maternal Basal Glycemia [mg/dL] 78.6 ± 6.9 89.3 ± 11.0 * 
 Gestational Age [wks] 39.1 ± 0.2 39.1 ± 0.3 
 Fetal Weight [g] 3420.0 ± 401.1 3390.3 ± 461.6 
Delivery Placental Weight [g] 479.0 ± 80.8 508.6 ± 80.7 
Data Placental Efficiency 7.34 ± 1.28 6.76 ± 1.01 
 Placental Area [cm2] 287.0 ± 77.5 247.51 ± 59.1 
 Placental Thickness [cm] 1.78 ± 0.56 2.19 ± 0.60 
 2 
Table 1: Maternal and delivery data (fetal and placental parameters). Data are presented 3 
as average ± SD. Student’s t-test: OB vs NW: *p≤ 0.05, ***p≤ 0.001. 4 
OB group: OB/GDM(-) and OB/GDM(+) grouped together. BMI: Body Mass Index; GDM: 5 
Gestational Diabetes Mellitus; GWG: Gestational Weight Gain; Placental Efficiency: 6 
fetal/placental weight ratio. 7 
 8 
  9 
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FIGURES LEGEND 1 
Figure 1: A) 2D scores plot showing PLS-DA discrimination between hydrophilic phases from 2 
placentas of OB vs NW and B) the corresponding VIP score plot. 3 
 4 
Figure 2: A) 2D scores plot showing PLS-DA discrimination between lipophilic phases from 5 
placentas of OB vs NW and B) the corresponding VIP score plot. 6 
 7 
 8 
SUPPLEMENTARY DATA FIGURES LEGEND 9 
Figure S1: A) 2D scores plot showing PLS-DA discrimination between hydrophilic phases 10 
from placentas of NW, OB/GDM(-), OB/GDM(+): accuracy= 0.61 R2 = 0.83 Q2 = 0.55; cross 11 
validation [CV] method: 10-fold CV, performance measure: prediction accuracy during training 12 
p<0.01; B) the corresponding VIP score plot. 13 
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